logo
Plus   Neg
Share
Email

Endo: Novitium Pharma Gets FDA Approval For Generic Equivalent Of Orfadin

Endo International plc (ENDP) said Novitium Pharma, a partner of Endo's subsidiary, has received approval from the FDA for a generic equivalent of Swedish Orphan Biovitrum's Orfadin. The Nitisinone capsules are used to treat patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Endo's operating company, Par Pharmaceutical Inc., plans to sell the product through specialty pharmacies beginning September.

Shares of Endo International plc were up more than 4 percent in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Back-to-school and college spending is projected to exceed the $100 billion mark for the first time ever ever despite the coronavirus pandemic, according to an annual survey by the National Retail Federation or NRF. The survey released by NRF and Prosper Insights & Analytics projects total spending for K-12 and college combined to reach $101.6 billion in 2020, up from last year's $80.7 billion. U.S. laboratory equipment maker Thermo Fisher Scientific Inc. (TMO) and Netherlands-based Qiagen N.V. (QGEN) announced Thursday that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of Qiagen. The... Morgan Stanley (MS) reported better-than-expected Q2 results, bolstered by strong trading revenues, amid the COVID-19 pandemic.
Follow RTT